title: Statins in low doses reduce VEGF and bFGF serum levels in patients with type 2 diabetes mellitus.
abstract: OBJECTIVE
  Recent experimental research revealed that statins at low doses induce angiogenesis, which in turn may be related to the course of atherosclerosis. There are no clinical studies evaluating the effect of 'low-dose' statins on serum levels of angiogenesis regulators in diabetic subjects. We aimed to explain how low doses of statins modify the serum concentrations of two potent proangiogenic factors, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), in patients with type 2 diabetes.
  
  
  METHODS
  Measurements of fasting glucose level, HbA1c, 1,5-anhydro-D-glucitol and lipid profile were taken from 47 patients with type 2 diabetes treated with low doses of atorvastatin (10 mg daily) or simvastatin (10-20 mg daily), from 45 statin-free patients with type 2 diabetes and from 23 nondiabetic subjects. Measurements of VEGF and bFGF in serum were taken using the BD™ Cytometric Bead Array.
  
  
  CONCLUSIONS
  Statins used in low doses in patients with type 2 diabetes reduce the serum concentration of VEGF and bFGF which suggests antiangiogenic potential of these doses. Nevertheless, this effect could be neutralized by postprandial hyperglycemia.
authors.affiliation: Department of Pharmacology, Poznan University of Medical Sciences, Poznan, Poland.
authors.forename: Marzena
authors.initials: M
authors.lastname: Dworacka
authors.forename: Ewa
authors.initials: E
authors.lastname: Krzyżagórska
authors.forename: Anna
authors.initials: A
authors.lastname: Wesołowska
authors.forename: Magdalena
authors.initials: M
authors.lastname: Borowska
authors.forename: Saule
authors.initials: S
authors.lastname: Iskakova
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Dworacki
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D003847:Deoxyglucose / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D008687:Metformin / Q000008:administration & dosage / Q000494:pharmacology*; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
chemical_list: D001786:Blood Glucose; D002784:Cholesterol; D003847:Deoxyglucose; D016222:Fibroblast Growth Factor 2; D006442:Glycated Hemoglobin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008687:Metformin; D014280:Triglycerides; D042461:Vascular Endothelial Growth Factor A; C467484:VEGFA protein, human; C517652:hemoglobin A1c protein, human; C006584:1,5-anhydroglucitol